Thrombotic thrombocytopenic purpura
Not recruitingStudy on the Safety and Effectiveness of TAK-755 (Apadamtase Alfa) for Patients with Severe Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
Study on the Safety and Effectiveness of TAK-755 (Apadamtase Alfa) for Patients with Severe Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
- Disease:Thrombotic thrombocytopenic purpura
- Substances:Apadamtase Alfa
Italy- Participants:0–17 years · 18–64 years · 65+ years
- Substances:Apadamtase Alfa
- Sponsor:Baxalta Innovations GmbH
















